Clinical utility and safety of MultiHance® in magnetic resonance imaging of liver cancer:: Results of multicenter studies in Europe and the USA

被引：13

作者：

Hamm, B

Kirchin, M

Pirovano, G

Spinazzi, A

机构：

[1] Bracco Ind Chim Spa, Med & Regulatory Affairs, I-20134 Milan, Italy

[2] Humboldt Univ, Dept Radiol, D-10117 Berlin, Germany

来源：

JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY | 1999年 / 23卷

关键词：

gadobenate dimeglumine; Gd-BOPTA; MR imaging; focal liver lesions;

D O I：

10.1097/00004728-199911001-00008

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

MultiHance(R) (gadobenate dimeglumine; Gd-BOPTA, Bracco SpA, Milano, Italy) is a novel gadolinium-based contrast agent which has recently been made commercially available in Europe for magnetic resonance imaging of the liver. It combines the properties of a conventional extracellular fluid contrast agent with those of a liver-specific agent and has been shown in numerous clinical trials to improve the impact of magnetic resonance imaging for both the detection and characterization of focal liver masses. The present article briefly summarizes the safety and efficacy results of Phase I, II and III clinical studies carried out in almost 800 patient and non-patient volunteers in both Europe and the USA.

引用

页码：S53 / S60

页数：8

共 50 条

[1] Results of a multicenter phase II clinical trial with a susceptibility contrast medium for magnetic resonance imaging of the liver
Balzer, T
Carter, EC
Shamsi, K
Niendorf, HP
ACADEMIC RADIOLOGY, 1996, 3 : S417 - S419
[2] MAGNETIC RESONANCE IMAGING AND PROSTATE CANCER: PERSPECTIVES FROM THE UK, EUROPE AND USA
Giganti, Francesco
Stabile, Armando
Moore, Caroline M.
ARCHIVOS ESPANOLES DE UROLOGIA, 2019, 72 (02): : 135 - 141
[3] Clinical late phase II trials of MultiHance® (Gd-BOPTA) for the magnetic resonance imaging of liver tumors in Japan
Kuwatsuru, R
Kadoya, M
Ohtomo, K
Tanimoto, A
Hirohashi, S
Murakami, T
Tanaka, Y
Yoshikawa, K
Katayama, H
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1999, 23 : S65 - S74
[4] Gadobenate dimeglumine 0.5 M solution for injection (MultiHance®) as contrast agent for magnetic resonance imaging of the liver:: Mechanistic studies in animals
de Haën, C
La Ferla, R
Maggioni, F
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1999, 23 : S169 - S179
[5] A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology
Runge, VM
Armstrong, MR
Barr, RG
Berger, BL
Czervionke, LF
Gonzalez, CF
Halford, HH
Kanal, E
Kuhn, MJ
Levin, JM
Low, RN
Tanenbaum, LN
Wang, AM
Wong, W
Yuh, WTC
Zoarski, GH
INVESTIGATIVE RADIOLOGY, 2001, 36 (02) : 65 - 71
[6] Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer
Afaq, Asim
Koh, Dow-Mu
Padhani, Anwar
van As, Nicholas
Sohaib, S. Aslam
BJU INTERNATIONAL, 2011, 108 (11) : 1716 - 1722
[7] CLINICAL UTILITY OF MAGNETIC-RESONANCE-IMAGING IN PEDIATRICS
COHEN, MD
AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1986, 140 (09): : 947 - 956
[8] Intraoperative magnetic resonance imaging in pediatric neurosurgery: safety and utility
Giordano, Mario
Samii, Amir
McLean, Anna C. Lawson
Bertalanffy, Helmut
Fahlbusch, Rudolf
Samii, Madjid
Di Rocco, Concezio
JOURNAL OF NEUROSURGERY-PEDIATRICS, 2017, 19 (01) : 77 - 84
[9] Clinical utility of magnetic resonance imaging and the preoperative identification of low risk endometrial cancer
Losco, G
Sykes, P
Anderson, N
Roberts, H
Fulton, J
Fraser, H
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2004, 44 (05): : 419 - 422
[10] MAGNETIC RESONANCE IMAGING-GUIDED BRACHYTHERAPY FOR CANCER OF CERVIX: CLINICAL RESULTS
Villafranca Iturre, E.
Romero, P.
Chicata, V.
Pellejero, S.
Lozares, S.
Vila, M.
Sola, A.
Rico, M.
Dominguez Dominguez, M.
Muruzabal, J. C.
Sanchez, C.
RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S264 - S264

← 1 2 3 4 5 →